Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Priority to ARP170102026ApriorityCriticalpatent/AR109102A1/en
Publication of AR109102A1publicationCriticalpatent/AR109102A1/en
Reivindicación 1: Un método para reducir el índice de masa ventricular izquierda (LVMi) en un paciente tratado previamente con una terapia de reemplazo enzimático (ERT) que sufre de la enfermedad de Fabry, caracterizado porque dicho método comprende administrar al paciente una formulación que comprende una cantidad eficaz de migalastat o una sal del mismo cada dos días, en donde la cantidad eficaz es de aproximadamente 123 mg de equivalente de base libre (FBE).Claim 1: A method for reducing the left ventricular mass index (LVMi) in a patient previously treated with an enzyme replacement therapy (ERT) suffering from Fabry's disease, characterized in that said method comprises administering to the patient a formulation comprising an effective amount of migalastat or a salt thereof every two days, wherein the effective amount is approximately 123 mg of free base equivalent (FBE).
ARP170102026A2017-07-192017-07-19
TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
AR109102A1
(en)